NCT03542643

Omega-3 Polyunsaturated Fatty Acids in Youth With ADHD

Completed NA Last updated 15 June 2018

What this trial tests

NA trial testing n-3 Polyunsaturated fatty acid in Attention Deficit Hyperactivity Disorder in 105 participants. Completed in 11 December 2017.

Timeline

7 July 2016

Primary endpoint
11 December 2017

11 December 2017

Quick facts

Lead sponsor	China Medical University Hospital
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	105
Start date	7 July 2016
Primary completion	11 December 2017
Estimated completion	11 December 2017
Sites	1 location across Taiwan

Drugs / interventions tested

• n-3 Polyunsaturated fatty acid
• Placebo

Conditions studied

• Attention Deficit Hyperactivity Disorder — all drugs for Attention Deficit Hyperactivity Disorder →
• ADHD — all drugs for ADHD →

Sponsor

China Medical University Hospital

Who can join

Adults 6 to 18, any sex, with Attention Deficit Hyperactivity Disorder or ADHD. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

N-3 polyunsaturated fatty acids(N-3 PUFAs) is important in balancing the immune function and crucial for the developing brain. Deficiency in n-3 PUFAs might be linked to the poor cognitive performances resulting in inattention and hyperactivity in youth with attention deficit hyperactivity disorder (ADHD). N-3 PUFAs appears to be a promising treatment that is safe, beneficial to youth with ADHD. In this proposal, investigators aim the test the hypothesis that n-3 polyunsaturated fatty acids will be more effective than placebo in improving cognitive function in youth with ADHD after 12 weeks of intervention.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

1. High-dose eicosapentaenoic acid (EPA) improves attention and vigilance in children and adolescents with attention deficit hyperactivity disorder (ADHD) and low endogenous EPA levels.
   Chang JP, Su KP, Mondelli V, Satyanarayanan SK, et al · · 2019 · cited 55× · PMID 31745072 · DOI 10.1038/s41398-019-0633-0
2. Polyunsaturated fatty acids (PUFA) for attention deficit hyperactivity disorder (ADHD) in children and adolescents.
   Gillies D, Leach MJ, Perez Algorta G. · · 2023 · cited 15× · PMID 37058600 · DOI 10.1002/14651858.cd007986.pub3